ACCESSWIRE
05 Aug 2022, 12:01 GMT+10
NEW YORK, NY / ACCESSWIRE / August 4, 2022 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Molecular Partners AG (NASDAQ:MOLN)
This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Molecular Partners American Depositary Shares pursuant and/or traceable to certain documents issued in connection with the Company's initial public offering conducted on or about June 16, 2021; and/or (b) Molecular Partners securities between June 16, 2021, and April 26, 2022.
A class action has commenced on behalf of certain shareholders in Molecular Partners AG. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's product, ensovibep, was less effective at treating COVID-19 than defendants had led investors to believe; that (ii) accordingly, the the U.S. Food and Drug Administration ('FDA') was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug Emergency Use Authorization ('EUA'); (iii) waning global rates of COVID-19 significantly reduced the Company's chances of securing EUA for ensovibep; (iv) another of the Company's product candidates, MP0310, was less attractive to Molecular Partners' collaborator, Amgen, than defendants had led investors to believe; (v) accordingly, there was a significant likelihood that Amgen would return to global rights of MP0310 to Molecular Partners; (vi) as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and (vii) as a result, documents issues in connection with the Company's initial public offer and defendants' public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
Shareholders may find more information at https://securitiesclasslaw.com/securities/moln-lawsuit-molecular-partners-loss-submission-form/?id=30596&from=1
17 Education & Technology Group Inc. (NASDAQ:YQ)
This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded 17EdTech securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with 17EdTech's December 2020 initial public offering.
A class action has commenced on behalf of certain shareholders in 17 Education & Technology Group Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) 17EdTech's K-12 Academic AST Services would end less than a year after the Company's initial public offering; (2) as part of its ongoing regulatory efforts, Chinese authorities would imminently curtail and/or end 17EdTech's core business; and (3) as a result, defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/17edtech-loss-submission-form/?id=30596&from=1
Enochian BioSciences, Inc. (NASDAQ:ENOB)
Investors Affected : January 17, 2018 - June 27, 2022
A class action has commenced on behalf of certain shareholders in Enochian BioSciences, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's co-founder and inventor Serhat Gumrukcu was engaged in a variety of frauds; (2) Gumrukcu was not a licensed doctor anywhere in the world; (4) as a result of the foregoing, Gumrukcu's purported contributions to the Company lacked a reasonable basis; (5) as a result of the foregoing, the Company had overstated its commercial prospects; (6) Gumrukcu had improperly diverted approximately $20 million from Enochian to entities he owned; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/enochian-biosciences-inc-loss-submission-form/?id=30596&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE : The Gross Law Firm
Get a daily dose of Baltimore Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Baltimore Star.
More InformationDHAKA, Bangladesh - Michelle Bachelet has urged the Bangladesh government to establish an independent investigation into allegations of enforced disappearances. ...
LONDON, England: Despite a legal challenge in London's High Court in early September, the UK government is continuing to pursue ...
NEW DELHI, India: During his national day address this week, Prime Minister NarendraModi said India will seek to become a ...
LONDON, England: The cap on flight departures from London's Heathrow Airport will beextended until October 29, airport officials announced.Heathrow capped ...
BERLIN, Germany: Highlighting Berlin's increasing focus on assisting in the Indo-Pacific region amidst rising tensions with China over Taiwan, Germany ...
PARIS, France: French firefighters have stopped the spread of a "monster" wildfire in the country's southwest, allowing the reopening of ...
NEW DELHI, India: After a decline in prices reaching a 2-year low encouraged investors to purchase silver in 2022, India's ...
NEW YORK CITY, New York: The American hedge fund Third Point has purchased a stake worth some $1 billion in ...
NEW YORK, New York - Investors were divided on Thursday as to where to send U.S. stocks. Jitters about inflation, ...
WELLINGTON, New Zealand: During his visit to New Zealand, Ambassador Sujiro Seam, Head of the Delegation of the European Union ...
BANGKOK, Thailand: Instant noodle makers have asked Thailand to allow them to increase their prices to meet rising costs, which ...
NEW YORK, New York - U.S. industrial stocks interrupted their five-day rally on Wednesday with all the major indices losing ...